Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A, Yuan W, Crespo M, Gurel B, Figueiredo I, Wotherspoon A, Miranda S, Riisnaes R, Ferreira A, Bertan C, Pereira R, Clarke M, Baker C, Ang JE, Fotiadis N, Tunariu N, Carreira S, Popat S, O'Brien M, Banerji U, de Bono J, Lopez J.
Minchom A, et al. Among authors: ang je.
J Immunother Cancer. 2020 Mar;8(1):e000713. doi: 10.1136/jitc-2020-000713.
J Immunother Cancer. 2020.
PMID: 32169873
Free PMC article.